Skip to Content

Ricky M. Schneider, MD

photo of Dr. Ricky Schneider
Telephone: 
(954) 227-7787
Fax: 
(954) 227-1787
Specialty/Specialties: 
Cardiovascular Disease
Holy Cross Medical Group: 
Yes

Office Hours
Monday-Friday | 9:00 am to 4:30 pm

Click here to view Dr. Schneider's Webisode. 

Current Leadership Position
Member, Cardiac Advisory Committee, Jim Moran Heart and Vascular Institute, Holy Cross Hospital
Vice-President, Board of Directors, Duke University Cooperative Cardiovascular Studies Group (DUCCS)

Focus Areas
Cardiology, Nuclear Cardiology, Preventive Cardiology

Certifications
American Board of Internal Medicine
American Board of Internal Medicine - Cardiovascular Disease
American Society of Nuclear Cardiology

Residency / Fellowship

Fellowship, Cardiology - Duke University Medical Center - Durham, NC (1980-1983)
Residency & Internship, Internal Medicine - Mount Sinai Medical Center - New York, NY (1977-1980)

Higher Education

Yale University School of Medicine - M.D. - New Haven, CT (1977)
Yale College - B.S. - New Haven, CT (1973)

Professional Associations

American Heart Association, Council on Clinical Cardiology
American College of Cardiology
American College of Physicians
Broward County Medical Association
Duke Cardiology Fellows Society
American Society of Nuclear Cardiology
Heart Failure Society of America

Awards
Regional Castle Connolly Top Doctor, Castle Connolly Medical, Ltd. (2009)
America’s Top Cardiologists, Consumers’ Research Council of America (2008)
Top Doctors, South Florida Consumers’ Checkbook Magazine (2002)
The Best Doctors in South Florida, Miami Metro Magazine (1998)

Research
Investigator, Extended Clinical Evaluation of Lovastatin (EXCEL) Study, Merck Sharp and Dohme Research Laboratories, West Point, PA; Duke University Cooperative Cardiovascular Studies (DUCCS) Consortium, 1988 - 1989 (17 patients enrolled)

Investigator, The Safety and Efficacy of Cardizem SR in Patients with Mild to Moderate Hypertension, Marion Laboratories, Inc., Kansas City, MO, 1988 - 1989 (6 patients enrolled)

Investigator, A Randomized Trial of Intravenous Heparin in Conjunction with Anistreplase (APSAC) in Acute Myocardial Infarction: DUCCS I Study, University Hospital, Tamarac, FL, Upjohn/SmithKline Beecham Pharmaceuticals, Philadelphia, PA, 8/90 - 7/91 (6 patients enrolled)

Investigator, A Randomized Trial of rt-PA (Activase) With Heparin versus APSAC (Eminase) Without Heparin in Patients With Acute Myocardial Infarction: DUCCS 2 Study, University Hospital, Tamarac, FL and Northwest Medical Center, Margate, FL, Upjohn/Smith Kline Beecham Pharmaceuticals, 1993 (terminated before patient enrollment at these hospitals)

Investigator, Global Utilization of Streptokinase or rt-PA for Occluded Coronary Arteries (GUSTO Study), University Hospital, Tamarac, FL and Northwest Medical Center, Margate, FL, Genentec Laboratories, 1992 - 1993 (respectively, 14 patients and 41 patients enrolled at these hospitals)

Investigator, Prospective Randomized Amiodipine Survival Evaluation (PRAISE Study), A Randomized, Double-blind, Dose-Titration, Parallel Group, Placebo-Controlled Study to Evaluate the Effect of Amiodipine on Mortality and Morbidity in Patients With Severe Heart Failure, including Extension Phase, DUCCS consortium, Pfizer Inc., Groton CT, 5/92 - 12/94 (11 patients enrolled)
 
Investigator, Losartan Exercise Study - US (LEXUS Study), A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Investigate the Effects of Losartan on the Exercise Capacity and Clinical Status of Patients with Symptomatic Heart Failure ■* US, Gas Exchange Substudy, including Extension Phase, DUCCS consortium, Merck & Co., Inc. West Point PA, 5/94 - 10/95 (6 patients enrolled)

Investigator, Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO Ha and Hb Study), Northwest Medical Center, Margate FL, Ciba-Geigy Corp., Summit NJ, 2/94 - 9/95 (10 patients and 17 patients enrolled in parts Ha and lib, respectively)

Investigator, Coumadin/Aspirin Reinfaretion Trial (CARS Trial), A Randomized, Double-Blind Study to Compare the Efficacy and Safety of Fixed Low Doses of Coumadin Plus Aspirin to Aspirin Alone in the Prevention of Reinfaretion, Cardiovascular Death, and Stroke' in Post-Myocardiat Infarction Patients, DUCCS consortium, Dupont Merck Laboratories, West Point PA, 4/95 - 2/96 (12 patients enrolled)

Investigator, Vesnarinone Trial (VEST Trial), A Randomized, Double-Blind, Placebo Controlled, Multiple Dose Study of the Chronic Administration of Vesnarinone in Heart Failure, Otsuka America Pharmaceutical, Inc., Rockville MD, 5/95 - 8/96 (13 patients enrolled)

Investigator, Prospective Randomized Amiodipine Survival EvaIuation-2 (PRAISE-2 Study), A Randomized, Double-Blind, Dose-Titration, Parallel Group, Placebo-Controlled Study to Evaluate the Effect of Amiodipine on Survival in Patients with Congestive Heart Failure, DUCCS Consortium, Pfizer Inc., Groton, CT, 1/96 - 2000 (3 patients enrolled)

Investigator, Acute Myocardial Infarction Study of Adenosine (AMISTAD study), A Randomized, Open-Label Triai of Adenosine as an Adjunct to rt-PA or Streptokinase (STQ in the Treatment of Acute Myocardial Infarction, Northwest Medical Center, Margate, FL, Medco Research, 3/96 - 3/97 (10 patients enrolled)

Investigator, Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III study), A Randomized Trial of Reteplase (r-PA) versus Accelerated Alteplase (t-PA) for the Treatment of Acute Myocardial Infarction, University Hospital, Tamarac, FL, Boehrmger Mannheim Therapeutics, 6/96 - 1/97 (17 patients enrolled)

Investigator, Platelet Hb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT study), A Randomized, Double-Blind Evaluation of the Efficacy and Safety of Integrilin versus Placebo for Reducing Mortality and (Re)infarction in Patients With Unstable Angina or Non-Q Wave Myocardial Infarction, University Hospital, Tamarac, FL, 9/96 - 1/97 (8 patients enrolled)

Investigator, Mode Selection Trial in Sinus Node Dysfunction (MOST study), National
Institutes of Health, Bethesda, MD; University Hospital, Tamarac, FL, Florida Medical Center,
 
Lauderdale Lakes, FL, Northwest Medical Center, Margate, FL, and Coral Springs Medical Center, Coral Springs, FL, 10/96 - 2001 (19 patients enrolled)

Investigator, A Randomized, Multicenter, Double-Blind, Placebo-Controlled Forced Dose Titration Study Comparing PPR Verapamil 240 rag/480 mg to Noryasc 5 mg/10 mg With and Without Atenolol SO mg in Patients With Chronic Stable Angina (Angina study), GD
Searle and Co., 11/96 - 4/97 (2 patients enrolled)

Investigator, Clinical Protocol for Controlled Onset Verapamil Investigation of Cardiovascular Endpoints (CONVINCE study), GD Searle and Co., 11/96 - 2001 (25 patients enrolled)

Investigator, Study of Patients Intolerant of Converting Enzyme Inhibitors (SPICE study),
Astra Hassle AB, 1/97 - 5/97 (3 patients enrolled)

Investigator, A Randomized, Double-Blind, Placebo-Controlled Trial of Sertraline (Zoloft) for Major Depression After Myocardial Infarction (SADHART trial), University Hospital, Tamarac, FL, Florida Medical Center, Lauderdale Lakes, FL, Northwest Medical Center, Margate, FL, and Coral Springs Medical Center, Coral Springs, FL, Pfizer Inc., Groton, CT> 6/97 - 10/97 (0 patients enrolled)

Investigator, Multi-Center, Double-Blind, Randomized, Trial of Single Bolus La note pin se Versus Accelerated Alteplase for the Treatment of Subjects With Acute Myocardial Infarction (InTime-II trial), University Hospital, Tamarac, FL, Bristol-Myers Squibb, 8/97 - 1998 (10 patients enrolled)

Investigator, Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME of CHF trial), University Hospital, Tamarac, FL, Florida Medical Center, Lauderdale Lakes, FL^ Northwest Medical Center, Margate, FL, and Coral Springs Medical Center, Coral Springs, FL, Sanofi Pharmaceuticals, Inc., 8/97 - 9/99 (9 patients enrolled)

Investigator, Efficacy and Safety of Xemilofiban Administration to Patients Undergoing Coronary Angioplasty or Stent Placement (EXCITE study), Florida Medical Center, Lauderdale Lakes, FL, GD Searle and Co., 9/97 - 1998 (11 patients enrolled)

Investigator, A Randomized, Double-Blind, Placebo Controlled Trial of the Effect of Weekly Azithromycin on the Incidence of Coronary Artery Disease in Subjects with Evidence of Exposure to C. Pneumoniae (WIZARD trial), Pfizer Central Research, 10/97 - 2002 (55 patients enrolled)

Investigator, A Phase III, Randomized, Double-Blind, Parallel-Group, International Trial of Single Bolus TNK-Tissue Plasminogen Activator (t-PA) Versus Accelerated Infusion of rt-PA (Alteplase, Activase) in Acute Myocardial Infarction (ASSENT II trial), Northwest Medical Center, Margate, FL, Boehringer Ingelheim France, 12/97 - 8/98 (2 patients enrolled)

Investigator, A Phase III, Multicenter, International, Randomized, Double-Blind, Aspirin-Controlled Study to Evaluate the Efficacy and Safety of Sibrafiban (Ro 48-3657), an Oral Platelet Glycoprotein Hb/IIIa Antagonist, as therapy for the Prevention of Secondary Vascular Events in Patients After an Acute Coronary Syndrome (SYMPHONY trial),
University Hospital, Tamarac, FL, Florida Medical Center, Lauderdale Lakes, FL, Northwest Medical Center, Margate, FL, and Coral Springs Medical Center, Coral Springs, FL, F. Hoffman-La Roche Ltd., 12/97- 8/99 (11 patients enrolled)

Investigator, The Effects of LDL-Cholesterol Lowering Beyond Currently Recommended Minimum Targets on Coronary Heart Disease (CHD) Recurrence in Patients with Pre-Existing CHD (Treating to New Targets, TNT Trial), Pfrzer/Parke-Davis, 6/98 - 12/04, (50 patients enrolled)

Investigator, PARAGON Trial, -A randomized, double-blind, placebo-controlled study of Lamifoban (Ro 44-9883) in patients with unstable angina / non-Q wave myocardial infarction, University Hospital, Tamarac, FL, F. Hoffman-La Roche Ltd., 08/98 - 1999 (0 patients enrolled)

Investigator, COPERNICUS Trial, A multicenter, randomized double-blind, placebo-controlled study to determine the effect of caryedilol on mortality in patients with severe chronic heart failure (MF 4477/SB 287) SmithKline Beecham Pharmaceuticals, 7/98 - 2000 (6 patients enrolled)

Investigator, 2nd SYMPHONY Trial, A Phase III, multicenter, international, randomized, double-blind, aspirin controlled trial to evaluate the efficacy and safety of two regimens with Xubix™ (sibrafiban; Ro48-3657), an oral platelet glycoprotein Hb/IIIa receptor antagonist, as therapy for the long term prevention of secondary vascular events in patients after an Acute Coronary Syndrome, University Hospital, Tamarac, FL, Florida Medical Center, Lauderdale Lakes, FL, Northwest Medical Center, Margate, FL, and Coral Springs Medical Center, Coral Springs, FL, F. Hoffman-La Roche Ltd., 1/99 - 8/99 (4 patients enrolled)

Investigator, VALIANT Trial, Multinational, multicenter, double-blind, randomized, active controlled, parallel group study comparing the efficacy and safety of long-term treatment with valsartan, captopril and their combination in high-risk patients after myocardial infarction, University Hospital, Tamarac, FL, Florida Medical Center, Lauderdale Lakes, FL, Northwest Medical Center, Margate, FL, and Coral Springs Medical Center, Coral Springs, FL, F. Hoffman-La Roche Ltd., 6/99 ~ 12/02 (5 patients enrolled)

Investigator, ADVANCE Trial, A 12 week, double-blind, placebo-controlled multicenter study of oral YM087 (CI- 1025) to assess functional capacity in patients with Class III Chronic Fleart Failure, Parke-Davis, (Protocol # 1025-14), 1/99 - 2000 (7 patients enrolled)

Investigator, CHARM Trial, Candesartan Cilexetil in Heart Failure: Assessment of Reduction in Mortality and Morbidity. Study of candesartan in patients with heart failure who are treated with ACE inhibitors and have depressed left ventricular systolic function (SH-AHS-006), Astra Zeneca, 8/99 - 7/03 (14 patients enrolled)

Investigator, GUSTO IV AMI Trial, A phase II, randomized, open-label trial evaluating the efficacy and safety of ReoPro® (Abciximab) in combination with reduced dose
Iff)

Retavase / Rapilysin™ (recombinant plasminogen activator, reteplase, r-PA) for the treatment of acute myocardial infarction (C0116T31), University Hospital;, Tamarac, FL and Florida Medical Center, Lauderdale Lakes, FL, Centocor, 9/99 — 2001 (10 patients enrolled)

Investigator, CURE Trial, A phase III randomized, double blind, parallel group clinical trial of clopidogrel versus placebo in patients with an acute coronary syndrome (unstable angina or myocardial infarction without ST segment elevation), (EFC 3307), Sanofi Pharmaceuticals, Inc., 10/99 - 6/00 (0 patients enrolled)

Investigator, WATCH Trial, Warfarin and antiplatelet therapy in chronic heart failure, VA Cooperative Studies Program #442, 10/99 - 7/03 (6 patients enrolled)

Investigator, a 12-Week Multicenter Randomized fiouble-BIind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of ZD4522 in the Treatment of Subjects with Hypertryglyceridemia (4522IL/0035), Astra Zeneca, 4/00 to 2001 (1 patient enrolled)

Investigator, 1 24-Week Randomized Double-Blind Multicenter Trial to Evaluate the Efficacy and Safety of Starting and Maximum Doses of ZD4522 and Atorvastatin in the Treatment of High Risk Hypercholesterolemic Subjects (4522IL/0025), Astra Zeneca, 3/00 to 2002 (3 patients enrolled)

Investigator, An Open-Label, Multinational, Multicentre, Extension Trial to Investigate the Long-Term Safety and Efficacy of ZD4522 in Subjects in the ZD4522 Clinical Trial Program (ZD4522IL/0034), Astra Zeneca, 7/00 - 11/04 (3 patients enrolled)

Investigator, A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HC1 vs. Glyburide in the Treatment of Subjects with Type 2 (Non - Insulin Dependent) Diabetes Mellitus and Mild to Moderate Congestive Heart Failure (01-00-TL-OPI-504),
Takeda Pharmaceuticals, 6/00 - 1/04 (3 patients enrolled)

Investigator, A Randomized, Double-Blind, Comparator-Controlled Study of Pioglitazone HC1 vs. Glyburide in the Treatment of Subjects with Type 2 (Non - Insulin Dependent) Diabetes Mellitus and Mild Cardiac Disease (01-00-TL-OPI-520), Takeda Pharmaceuticals, 5/01 - 1/03 (5 patients enrolled)

Investigator, Efficacy and Safety Study of the Oral Direct Thrombin Inhibitor H376/9S Compared with Dose-Adjusted Warfarin (Coumadin) in the Prevention of Stroke and Systemic Embolic Events in Patients with Atrial Fibrillation (SPORTIF V) (233:SH-TPA-0005), Astra Zeneca, 9/00 - 3/03 (6 patients enrolled)

Sub-Investigator, Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT) (CV 123-229) Protocol (IND Nos. 27,201 and 52,081), US and Canada, Bristol Meyers Squibb, 10/00 - 10/03 (5 patients enrolled)

Investigator, A Research Study to Evaluate the Initiation of Coreg at Discharge in Hospitalized Patients with Heart Failure (Initiation Management Predischarge: Assessment of Coreg Therapy for Heart Failure (IMPACT-HF), SmithKline Beecham, 9/01 - 2003 (3 patients enrolled)

Investigator, Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) (CV 131-148), Bristol-Myers Squibb, 8/02 - 8/04 (1 patient enrolled)
Investigator, A Randomized, Double-Blind, Multicenter Study Comparing the Glycemic Control Characteristics of Carvedilol and Metoprolol in Hypertensive Patients with Type II Diabetes Mellitus (GEMINI n), Protocol 105517/346, Glaxo SmithKline, 4/02 - 10/03 (7 patients enrolled)

Investigator, Aggressive Reduction of Inflammation Stops Events (ARISE), Protocol AGI-1067-042, AtheroGenics, 8/03 - 9/06 (15 patients enrolled)

Investigator, The Efficacy and Safety of Avalide 150/12.5 mg and Avalide 300/25 mg in Patients with Hypertension Uncontrolled on Monotherapy (INCLUSIVE), Protocol L8829 CV 131-170, Bristol-Myers Squibb and Sanofi-Synthelabo, 8/03 - 5/04 (1 patient enrolled)

Investigator, Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events (ACTIVE), Protocol EFC4912, Sanofi-Synthelabo, 9/03 - 11/09 (17 patients enrolled)

Investigator, Trial to Assess Chelation Therapy (TACT), Protocol U01 AT001156-01,
National Heart, Lung and Blood Institute (NHLBI), National Center for Complementary and Alternative Medicine (NCCAM), 10/03 - 4/2010 (4 patients enrolled)

Investigator, A 26-week, Double Blind, Randomized, Multi-centre, Phase Illb, Parallel Group Study to Compare the Efficacy and Safety of Rosuvastatin (40mg) with Atorvastatin (80mg) in Subjects with Hypercholesterolemia and Coronary Heart Disease or CHD Risk Equivalents (POLARIS), Protocol 4522IL/016, AstraZeneca, 11/03 - 9/04 (1 patient enrolled)

Investigator, A Phase III, Randomized, Double-Blind Study of Intravenous CVT-314'6 vs. Adenoscan in Patients Undergoing Stress Myocardial Perfusion Imaging, Protocol CVT 5132, CV Therapeutics, 6/04 - 4/05 (11 patients enrolled)

Investigator, A Phase III, Randomized, Double-Blind Study of Intravenous CVT-3146 vs. Adenoscan in Patients Undergoing Stress Myocardial Perfusion Imaging, Protocol CVT 5131, CV Therapeutics, 5/05 - 10/06 (16 patients enrolled)

Investigator, Analysis of a New AT/AF Detection Algorithm in Patients with Atrial Arrhythmias (AWARE), St. Jude Medical, 4/05 - 5/06 (12 patients enrolled)

Investigator, A Randomized, Double-Blind, Placebo-Controlled* Multicenter, Phase III Study of Rosuvastatin (Crestor®) 20 mg in the Primary Prevention of Cardiovascular Events Among Subjects with Low Levels of LDL-Cholesterol and Elevated Levels of C-Reactive Protein (JTJPIXER), Protocol 4522US/0011, AstraZeneca Pharmaceuticals LP, 7/05 - 5/08 (5 patients enrolled)

Investigator, A Phase III, Multicenter, Randomized, Double-Blind, Placebo-controlled study to Evaluate the Long Term Efficacy and Safety of Oral Tolyaptan in Subjects Hospitalized with Worsening Congestive Heart Failure (EVEREST), Protocol 156-03-236,
Otsuka Maryland Research Institute, Inc., 8/05 - 10/06 (4 patients enrolled)

Investigator, A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention (TIMI38) (Protocol LV640315), EH Lilly and Company, 10/05 - 10/07 (6 patients enrolled)

Investigator, A Phase III, Parallel, Double-Blind, Multicenter Trial to Examine Inducible Myocardial Perfusion Abnormality Detection With BMS068645 and Adenosine Stress Photon Emission Computed Tomography (SPECT) Compared to Coronary Angiography (Protocol BMS068645-302), Bristol-Myers Squibb Medical Imaging, 1/06 -2/06 (1 patient enrolled)

Investigator, A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin vs. Simvastatin Monotherapy in High-Risk Subjects Presenting with Acute Coronary Syndrome (IMPROVE-IT), Protocol P04103, Schering-Plough Research Institute, Inc., 1/06 - present (8 patients enrolled)

Investigator, Randomized Evaluation of Long term Anticoagulant Therapy (RE-LY) Comparing the Efficacy and Safety of Two Blinded Doses of Dabigatran etexilate with Open Label warfarin for the Prevention Of Stroke and Systemic Embolism in Patients with Non-valvular Atrial Fibrillation: Prospective, Multi-centre, Parallel-group, Non-inferiority trial, Boehringer Ingelheim International GmbH, 2/06 - 2/09 (19 patients enrolled)

Investigator, Follow-up of Clinical Outcomes: The Long Term AGI-1067 plus Usual Care Study (FOCUS), Protocol AGI-1067-051, AtheroGenics Inc., 9/06 - 6/07 (11 patients enrolled)

Investigator, A Randomized, Double-blind, Parallel-group, Placebo-Controlled, Multinational Clinical Trial to Evaluate the Efficacy of Aliskiren and Valsartan versus Placebo in Lowering Levels with NT-proBNP in Stabilized Patients Post Acute Coronary Syndromes (AVANT-GARDE), Protocol CSPP100A2347, Novartis Pharmaceuticals Corporation, 4/07 - 5/09 (0 patients enrolled)

Investigator, A Phase III Randomized, Double-blind, Placebo-Controlled, Multi-Center, Parallel Group Study to Evaluate the Efficacy and Safety of Fixed doses of Darusentan in Subjects with Resistant Systolic Hypertension Receiving Combination Therapy with Four or More Antihypertensive Drugs, Including a Diuretic (DORADO), Protocol DAR-311,
Giiead Sciences, Inc., 9/06 - 4/08 (0 patients enrolled)

Investigator, Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (TMPROVE-HF), Protocol AMG-04-002, Medtronic Inc., 5/05 - 10/09 (95 patients registered)

Investigator, A Placebo-controlled, Double-blind, Parallel Arm Trial to Assess the Efficacy of Dronedarone 4G0mg bid for the Prevention of Cardiovascular Hospitalization or Death from any Cause in Patients with Atrial Fibrillation/Atrial Flutter (ATHENA), Protocol
EFC5555, sanofi-sythelabo/aventis, 7/05 - 3/08 (1 patient enrolled)

Investigator, A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Darbopoetin alfa Treatment on Mortality and Morbidity in Heart Failure with Symptomatic Left Ventricular Systolic Dysfunction and Anemia (RED-HF), Protocol 20050222, Amgen, Inc. 9/06 - 10/07 (0 Patients enrolled)

Investigator, A Prospective, Randomized, Double-blind, Double-Dummy, Parallel-Group, Multicenter, Event-Driven, Non-inferiority Study Comparing the Efficacy and Safety of Once-Daily Oral Rivaroxaban (BAY 59-7939) with Adjusted-Dose Oral Warfarin for the Prevention of stroke and Non-Central Nervous System Systemic Embolism in Subjects with Non-Valvular Atrial Fibrillation (ROCKET AF, Protocol 39039039AFL3001, Johnson and Johnson Pharmaceutical Research and Development, LLC, 2/07 — 10/2010 (9 patients enrolled)

Investigator, A Randomized, Double-blind Trial to Test Higher versus Lower Doses of Aspirin on Inflammatory Markers and Platelet Biomarkers and Nitric Oxide Formation and Endothelial Function in Secondary Prevention (TAD), Bayer; 10/06 - 6/07 (30 patients enrolled)

Investigator, A Multicenter, Randomized, Double-blind, Prospective Study Comparing the Safety and Efficacy of Fenofibric Acid and Simvastatin Combination Therapy to Fenofibric Acid and Simvastatin Montherapy in Subjects with Mixed Dyslipidemia, Protocol M05-749, Abbott, 5/06 - 6/07 (1 patient enrolled)

Investigator, Registry of AT/AF Episodes in the CRM Device Population: RATE Registry,
St. Jude Medical, 6/07 - present (7 patients enrolled)

Investigator, The TIMI-38 Coronary Stent Registry: Long-Term Follow Up of Subjects with PCI and Stenting for ACS, Eli Liiiy and Company, 4/07 -10/2010(6 patients enrolled)

Investigator, A study of Telemonitoring to Improve Heart Failure Outcomes (Tele-HF),
National Institute of Health, 9/07 - 9/2010 (21 patients enrolled)

Investigator, Apixaban Versus Acetylsalicylie Acid (ASA) to Prevent Stroke in Atrial Fibrillation Patients Who Have Failed or are Unsuitable for Vitamin K Antagonist Treatment: A Randomized Double Blind Trial (AVERROES), Bristol-Myers Squibb, 12/07¬8/2010 (4 patients enrolled)

Investigator, Warfarin Versus Aspirin In Reduced Cardiac Ejection Fraction (WARCEF),
National Institute of Neurological Disorders and Stroke, 5/07-present (3 patients enrolled)

Investigator, Protocol 1160.67: RandomisEd Dabigatran Etexilate dose finding study in patients with acute coronary syndromes post index Event with additional risk factors for cardiovascular complications also receiving aspirin and clopidogril: Multi-center, prospective, placebo controlled, group dose escalation trial (RE-DEEM), Boehringer-Ingelheim, 5/08 - 12/08 (0 patients enrolled)

Investigator, Protocol H7T-MC-TABY: A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome (ACS) Subjects with Unstable Angina/Non-ST-Elevation Myocardial Infarction (UA/NSTEM3) Who are Medically Managed - The TRILOGY ACS Study, Eli Lilly and Company, 5/08 - 09 (0 patients enrolled)

Investigator, Protocol CDx000004: Identification of Gene Expression Patterns in Circulating Cells that Predict the presence of Coronary Artery Disease - The PREDICT Study - Personalized Risk Evaluation and Diagnosis In the Coronary Tree. Cardio Dx Inc, 10/08 -present (13 patients enrolled)

Investigator, Protocol 3606-CL-3002 A Phase 3b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Caffeine Intake on Single Photon Emission Computed Tomography (SPECT). Myocardial Perfusion in Subjects Administered Regadenoson. Astellas, 12/08 - 9/2010 (2 patients enrolled)

Investigator, Protocol DU176b-C-U301 - A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Multicenter, Multi-National Study For Evaluation of Efficacy and Safety Of DU-176b Versus Warfarin in Subjects with Atrial Fibrillation - Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation (ENGAGE-AF).
Daiichi Sankyo, 1/09 — present (8 patients enrolled)

Investigator, Protocol 1160.71: Long term multi-center extension of dabigatran treatment in patients with atrial fibrillation who completed the RE-LY trial and a cluster randomised trial to assess the effect of a knowledge translation intervention on patient outcomes (RELY-ABLE). Boehringer Ingelheim International 03/09 - present (13patients enrolled)

Investigator, Protocol BC22140 ROW: A Multicenter, randomized, double-blinded, placebo-controlled cardiovascular outcomes study to evaluate the potential of Aleglitazar to reduce cardiovascular risk in patients with a recent Acute Coronary Syndrome (ACS) event and type 2 Diabetes — ALECARDIO. Hofftnan-La Roche, Inc, 2/10 to present (1 patients enrolled)

Investigator, Protocol D1680C00003: A Multicenter, randomized, double-blind, placebo-controlled Phase IV trial to evaluate the effect of Saxagliptin on the Incidence of Cardiovascular death, Myocardial Infarction or Ischaemic stroke in patients with Type 2 Diabetes - SAVOR-TIMI53. AstraZeneca, 4/2010 to present (8 patients enrolled).

Investigator, DUCCS- BI- Registry: A retrospective study to assess the quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation. DUCCS with Boehringer Ingelheim. 4/2010 to 10/2010 (40 patients enrolled).

Investigator, Protocol RIVAROXAFL4001: A Multicenter, prospective outpatient disease registry to identify "real world" treatment patterns of atrial fibrillation according to patient demographics, clinical factors, risk stratification and geographic regions. Ortho-McNeil Janssen Scientific Affairs, LLC. 5/2010 to present (44 patients enrolled).

Investigator* A multicenter randomized trial to determine whether an initial non-invasive anatomic imaging strategy with coronary CT angiography (CTA) will improve clinical outcomes in subjects with symptoms concerning for coronary artery disease relative to an initial functional testing strategy (usual care) — PROMISE. National Hearty Lung and Blood Institute (NHLBI). 5/2010 to present (3 patients enrolled).

Investigator, D5132C00001: A randomized, double-blind, placebo controlled, parallel group, multinational trial, to assess the prevention of thrombotic events with Ticagrelor compared to placebo on a background of acetyl salicylic acid (ASA) therapy in patients with history of myocardial infarction - PEGASUS-TIMI54. AstraZeneca. Screening began 1/2011- open to enrollment 3/1/2011.

Investigator, LCZ696B2314: A multicenter, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to enalapril on morbidity and mortality in patients with chronic heart failure and reduced ejection fraction - PARADIGM-HF. Novartis. Screening began 2/2011; open to enrollment 3/2011

Publications

Schneider RM, Hayslett JP, Downing SE, Berger HJ, Donabedian RK, Zaret BL: Effect of methylprednisolone upon technetium-9 9m pyrophosphate assessment of myocardial necrosis in the canine countershock model. Circulation 56: 1029-1034, 1977

Schneider RM, Worsley A, Lichtman S, Meyer RJ: Sarcoidosis with immune hemolytic anemia and thrombocytopenia; Humoral aberrations responding to steroids or splenectomy. Mt. Sinai J Med 49:1 15-120, I9S2

Schneider RM, Seaworth JF, Dohrmann ML, Lester RM, Phillips HR, Bashore TM, Baker JT: Anatomic and prognostic implications of an early positive treadmill exercise test. Am J Cardiol 50:682-688, 1982

Schneider RM, Forties RE, Stuckey WL, Gilbert RD, Peter RH: Fracture of a polyurethane cardiac catheter in the aortic arch: A complication related to catheter aging. Cath and Cardiovasc Diag 9: 197-207, 1983

Schneider RM, Seaworth JF, Baker JT: Early positive exercise test: Implications for prognosis. Primary Cardiol 9:49-55, 1983

Schneider RM, Roberts KB, Morris KG, Stanfeld JA, Cobb FR: Relation between radionuclide angiographic regional ejection fraction and left ventricular regional ischemia in awake dogs. Am J Cardiol 53:294-301, 1984

Schneider RM, Jaszczak RJ, Coleman RE, Cobb FR: Disproportionate effects of regional hypokinesis on radionuclide ejection fraction: Compensation using attenuation-corrected ventricular volumes. JNuclMed25: 747-754, 1984

Schneider RM, Chu A, Akaishi M. Weintraub WS, Morris KG, Cobb FR: Left ventricular ejection fraction after acute coronary occlusion in conscious dogs: Relation to the extent and site of myocardial infarction. Circulation 72:632-638, 1985

Akaishi M. Schneider RM, Mercier RJ, Naccarella FF, Agarwal JB, Helfant RH, Weintraub WS: Relationship between left ventricular global and regional function and extent of myocardial ischemia in the canine heart. J Am Coll Cardiol 6: 104-112, 1985

Schneider RM, Helfant RH: Timing of surgery in chronic mitral and aortic regurgitation. (Book Chapter) In; "Valvular Heart Disease," Albert Brest, ed. Cardiovascular Clinics 361-374, 198.5

Weintraub WS, Schneider RM, Seelaus PA, Agarwal JB, Helfant RH: Prospective evaluation of the severity of coronary artery disease with exercise radionuclide angiography and electrocardiography. Am Heart J111:537-542, 1986

Schneider RM, Weintraub WS, Klein LW, Seelaus PA, Katz RJ, Agarwal JB, Helfant RH: Multistage analysis of exercise ejection fraction in coronary artery disease. Am J Cardiol 58:3641, 1986

Schneider RM, Weintraub WS, Klein LW, Agarwal JB, Helfant RH: Rate of left ventricular functional recovery by radionuclide angiography after exercise in coronary artery disease. Am J Cardiol 57:927-932, 1986

Klein LW, Agarwal JB, Schneider RM, Hermann G. Weintraub WS, Helfant RH: Effects of previous myocardial infarction on measurements of reactive hyperemia and the coronary vascular reserve. J Am Colt Cardiol 8:357-363, 1986
 
Akaishi M. Weintraub WS, Schneider RM, Klein LW, Agarwal JB, Helfant RH: Analysis of systolic bulging: Mechanical characteristics of acutely ischemic myocardium in the conscious dog. Circ Res 58:209-217, 1986

Klein LW, Weintraub WS, Agarwal JB, Schnneider RM, Seelaus P. Katz RI, Helfant RH: Prognostic significance of severe narrowing of the proximal segment of the left anterior descending coronary artery. Am J Cardiol 58:42-46, 1986

Akaishi M. Schneider RM, Mercier RJ, Agarwal JB, Helfant RH, Weintraub WS: Analysis of phases of contraction during graded acute myocardial ischemia. Am J Physiol 250:H778-785, 1986

Akaishi M, Weintraub WS, Mercier RJ, Agarwal JB, Schneider RM, Helfant RH: The
significance of underlying coronary stenosis for recovery of myocardial function after transient
ischemia in the dog. Am Heart J 112:1226-1231, 1986

Wynant GE, Schneider RM, Akaishi M. Rubenstein Rl, Askenase AD, Seelaus PA* Klein LW, Agarwal JB, Weintraub WS, Helfant RH: Experimental and clinical validation of a radionuclide angiographic method for assessing myocardial dyskinesis. J NuclMed Technol, September 1986

Klein LW, Agarwal JB, Rosenberg MC, Stets G. Weintraub WS, Schneider RM, Hermann G. Helfant RH: Assessment of coronary artery stenosis by digital subtraction angiography: A pathoanatomic validation. Am Heart /113:1011-1017,1987

Schneider RM, Morris KG, Chu A, Roberts KB, Coleman RE, Cobb FR: Relation between myocardial perfusion and left ventricular function following acute coronary occlusion: Disproportionate effects of anterior vs. inferior ischemia. Circ Res 60:60-71, 1987

Vigilante GJ, Weintraub WS, Klein LW, Schneider RM, Seelaus PA, Parr GVS, Lemole G. Agarwal JB, Helfant RH: Improved survival with coronary bypass surgery in patients with three vessel coronary disease and abnormal left ventricular function: Matched case-control study in patients with potentially operable disease. Am J Med 82:697-702, 1987

Klein LW, Askenase AD, Weintraub WS, Akaishi M. Mercier RJ, Schneider RM, Agarwal J. Helfant RH: Absence of coronary vascular reserve in myocardium distal to a fixed coronary stenosis. Cardiovasc Res 21:99-106, 1987

Akaishi M. Schneider RM, Seelaus PA, Klein LW, Agarwal JB, Helfant RH, Weintraub WS: A non-linear elastic model of contraction of ischemic segments. Cardiovasc Res 22:889-899; 1988

Davidson RM, McNeer JF, Logan L, Higginbotham MB, Anderson J, Blackshear J, Chu A, Hettleman B, McGrew F, Meese R, O'Connor C, Schneider RM, Wagner GS, EXERDUCCS
 
Investigators: A cooperative network of trained sites for the conduct of a complex clinical trial: a new concept in multicenter clinical research. Am Heart J151:451-456,2006

Hennekens CHS Schneider WR, Schneider RM. Fish Oils and Stroke. (Book Chapter) In: Fatty Acids in Health Promotion and Disease Causation. Watson RR, ed. AOCS Press, Urbana, IL, 2008

Location

2901 Coral Hills Drive, Suite 240
Coral Springs, FL 33065

HCMG Practice Locations

Map

My Health Patient Portal